Is Metagenomi, Inc. (MGX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 82.4% / 30% | 446.8% / 30% | 2.3% / 30% | 28.15% / 5% | ✗ NOT HALAL |
| DJIM | 82.4% / 33% | 446.8% / 33% | 2.3% / 33% | 28.15% / 5% | ✗ NOT HALAL |
| MSCI | 14.1% / 33% | 76.5% / 33% | 0.4% / 33% | 28.15% / 5% | ✗ NOT HALAL |
| S&P | 82.4% / 33% | 446.8% / 33% | 2.3% / 33% | 28.15% / 5% | ✗ NOT HALAL |
| FTSE | 14.1% / 33% | 76.5% / 33% | 0.4% / 50% | 28.15% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -274.6% | |
| Operating Margin | -623.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -44.7% | |
| Return on Assets (ROA) | -22.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$89M |
| Free Cash Flow | -$89M |
| Total Debt | $41M |
| Debt-to-Equity | 25.6 |
| Current Ratio | 7.2 |
| Total Assets | $221M |
Price & Trading
| Last Close | $1.39 |
| 50-Day MA | $1.53 |
| 200-Day MA | $1.90 |
| Avg Volume | 270K |
| Beta | 0.5 |
|
52-Week Range
$1.23
| |
About Metagenomi, Inc. (MGX)
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Metagenomi, Inc. (MGX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Metagenomi, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Metagenomi, Inc.'s debt ratio?
Metagenomi, Inc.'s debt ratio is 82.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 14.1%.
What are Metagenomi, Inc.'s key financial metrics?
Metagenomi, Inc. has a market capitalization of $50M, and revenue of $25M. Return on equity stands at -44.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.